Clinical Research Directory
Browse clinical research sites, groups, and studies.
Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV
Sponsor: Hôpital Européen Marseille
Summary
Analysis of gut microbiota becomes more and more accessible in recent years. Experimental data in both animal and human studies have demonstrated that imbalance of the gut microbiota which is called symbiosis may participate in an accelerated procedure of ageing as well as the expression of frailty phenotype. People living with HIV (PLHIV) present markers of phenotypic frailty on average 10 years before uninfected people. In this population structural and functional modifications of GALT (Gut Associated Lymphoid Tissue) are observed early after HIV infection and persist despite virological suppression on ART (AntiRetroviral Treatment). These GALT modifications are associated with microbial translocation that is also correlated with immune activation and dysbiosis. The objective of study is to explore gut microbiota of PLWH over 5 years, as well as to study associations of its longitudinal evolution with frailty markers and burden of comorbidities.
Key Details
Gender
All
Age Range
55 Years - Any
Study Type
OBSERVATIONAL
Enrollment
132
Start Date
2023-12-05
Completion Date
2030-03
Last Updated
2025-09-25
Healthy Volunteers
No
Conditions
Interventions
Stool sampling
Stool samples will be collected from participants at baseline and annually during 5 years
Frailty phenotype
According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
Blood plasma collection
Blood plasma collection to measure persistent inflammation and immune activation
Locations (1)
Hôpital Européen Marseille
Marseille, France